Daily Management Review

$5.2 Billion Purchase Deal As Agrees To Buy Drug Ingredients Maker Patheon


05/16/2017




$5.2 Billion Purchase Deal As  Agrees To Buy Drug Ingredients Maker Patheon
As Thermo Fisher Scientific Inc looks to become a one-stop shop for contract drug development and manufacturing, the company has said that it would buy Dutch drug ingredients maker Patheon NV.
 
A premium of about 35 percent to Patheon's Friday close is represented by the offer price of $35 per share. Just shy of the offer, Patheon's shares were trading at $34.60.
 
Research, clinical trial and production services to the biopharmaceutical industry is provided by Thermo Fisher which is the world's No. 1 maker of scientific instruments. From regulatory consulting to making drug ingredients and finished medicines, a very wide range of services are offered by Patheon.
 
The global contract development and manufacturing market, which the company estimates is worth about $40 billion, is fragmented at present and the Patheon's drug manufacturing abilities will help Thermo Fisher grab a bigger slice of the fragmented market, the company hopes as drugmakers increasingly vie to shave costs and clinical trial times.
 
"Thermo Fisher already had a developing and strong position in clinical trial manufacturing and now expands that arm into drug manufacturing, which is likely to highlight its growing presence in the market of bioproduction and bioprocessing," Leerink analysts wrote in a client note.
 
Saying it would merge with inVentiv Health Inc in a $4.6 billion deal to help it win contracts with large pharma companies, the contract research space is in the midst of a wave of consolidation with INC Research Holdings Inc last week.
 
A purchase price of about $7.2 billion is represented by the Patheon deal, including debt. About $1.9 billion in revenue last year was generated by Patheon, which went public last July.
 
Jefferies analysts said that the acquisition follows a difficult start to its public life even though the company – Patheon, has manufactured more U.S. Food and Drug Administration approved products than any peer.
 
The deal will immediately add to Thermo Fisher's adjusted profit by 30 cents in the first full year after close and is expected to be completed by the end of 2017.
 
Thermo Fisher has entered into agreements with affiliates of JLL Partners and Royal DSM, whose holdings represent about 73 percent of Patheon shares, under which they will tender their shares in the transaction.
 
Wachtell, Lipton, Rosen & Katz is serving as legal counsel and Goldman Sachs & Co is acting as financial adviser to Thermo Fisher. Skadden, Arps, Slate, Meagher & Flom LLP is its legal counsel and Morgan Stanley & Co is Patheon's financial adviser.
 
(Source:www.reuters.com) 






Science & Technology

With China Set To Dominate, 1 Billion Could Be Using 5G By 2023

Deutsche Telekom unveils next gen 5G mobile antennas in Europe

Diamonds are now the new gold

Expert Body Says Driving In A Driverless Car In An Inebriated Condition Or On Drugs Should Be Legalized

SEC’s EDGAR database vulnerable to cyber threats

Research Says The Risk Of Severe Turbulence On Planes Will Increase Due To Climate Change

Barclays and CLS Group aim to replace SWIFT with blockchain

Designing Of Cars Being Done With Hologram Goggles At Ford

The Already Surging Cyber Attacks Are Set To Rise Even Further, Says A Study

Chinese to equip smartphones with OLED displays

World Politics

World & Politics

Scholar Says Political Appointees Not As Important As Financial Ones In China For The Economy

An Expected Change In Brussels Could Be Crucial For The Euro Zone

Destroying People Who Wouldn't Help One Of His Bankrupt Businesses Was All Trump Talked About When He Met Him In 1990s: Branson

Russia Is Worried About America’s Unpredictability

No oil contracts with Iraqi Kurdistan: Iraq’s oil ministry

Donald Trump lost $ 600 million during his presidency

Britain puts its weight behind Europe in the battle between Boeing and Bombardier

EU hopes to keep the Iran nuclear deal afloat